Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA Administered to Healthy Children From 9 Months of Age
Brief Summary: The primary study objectives are:

* To demonstrate that a 2-dose regimen of ProQuad® manufactured with recombinant Human Albumin (rHA) administered at a 3-month interval to healthy children of 11 months of age at the time of Dose 1 is as immunogenic as in healthy children of 12 months of age at the time of Dose 1.
* To demonstrate that a 2-dose regimen of ProQuad® rHA administered at a 3-month interval to healthy children of 9 months of age at the time of Dose 1 is as immunogenic as in healthy children of 12 months of age at the time of Dose 1.
* To demonstrate that a 2-dose regimen of ProQuad® rHA administered at a 3-month interval to healthy children of 11 months of age and 9 months of age at the time of Dose 1 is well-tolerated compared to children of 12 months of age at the time of Dose 1.

The first primary hypothesis was that a 2-dose regimen of ProQuad® rHA, administered at a 3-month interval to children of 11 months of age, would be non-inferior in terms of antibody response rates to measles, mumps, rubella, and varicella at Day 42 following Dose 2, to the same regimen in children of 12 months of age at the time of Dose 1.

If the first primary hypothesis was demonstrated, the second primary hypothesis was that a 2-dose regimen of ProQuad® rHA, administered at a 3-month interval to children of 9 months of age, would be non-inferior in terms of antibody response rates to measles, mumps, rubella, and varicella at Day 42 following Dose 2, to the same regimen in children of 12 months of age at the time of Dose 1.

The secondary study objectives are:

* To describe the antibody titres to measles, mumps, rubella and varicella at Day 42 following Dose 1 and Dose 2 of ProQuad® rHA administered to healthy children from 9 months of age.
* To evaluate the safety profile of Dose 1 and Dose 2 of ProQuad® rHA administered to healthy children from 9 months of age.


Options:
A: Arm Label: Arm 1: ProQuad® at 9 and 12 months; Type: EXPERIMENTAL; Interventions: Biological: ProQuad® manufactured with recombinant Human Albumin (rHA) | Arm Label: Arm 2: ProQuad® at 11 and 14 months; Type: EXPERIMENTAL; Interventions: Biological: ProQuad® manufactured with recombinant Human Albumin (rHA) | Arm Label: Arm 3: ProQuad at 12 and 15 months; Type: ACTIVE_COMPARATOR; Interventions: Biological: ProQuad® manufactured with recombinant Human Albumin (rHA) | Intervention Type: BIOLOGICAL; Name: ProQuad® manufactured with recombinant Human Albumin (rHA); Assigned to Arm(s): Arm 1: ProQuad® at 9 and 12 months, Arm 2: ProQuad® at 11 and 14 months, Arm 3: ProQuad at 12 and 15 months
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: Priorix-Tetra™ (MMRV vaccine 208136), Biological: Havrix®, Biological: Prevnar® | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Biological: Priorix-Tetra™ (MMRV vaccine 208136), Biological: Havrix®, Biological: Prevnar® | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Biological: ProQuad®, Biological: Havrix®, Biological: Prevnar® | Intervention Type: BIOLOGICAL; Name: Priorix-Tetra™ (MMRV vaccine 208136); Assigned to Arm(s): Group A, Group B | Intervention Type: BIOLOGICAL; Name: ProQuad®; Assigned to Arm(s): Group C | Intervention Type: BIOLOGICAL; Name: Havrix®; Assigned to Arm(s): Group A, Group B, Group C | Intervention Type: BIOLOGICAL; Name: Prevnar®; Assigned to Arm(s): Group A, Group B, Group C
C: Intervention Type: BIOLOGICAL; Name: M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®; Assigned to Arm(s): N/A
D: Arm Label: Priorix-Tetra new WS Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' 208136, new formulation | Arm Label: Priorix-Tetra current WS Group; Type: EXPERIMENTAL; Interventions: Biological: Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine) | Intervention Type: BIOLOGICAL; Name: Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine); Assigned to Arm(s): Priorix-Tetra current WS Group | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' 208136, new formulation; Assigned to Arm(s): Priorix-Tetra new WS Group

Answer: A